Navidea Biopharmaceuticals has secured regulatory approval from India's Central Drugs Standard Control Organization for its technetium-99m (Tc99m) tilmanocept radiopharmaceutical Lymphoseek.
The agent is called Lymphoaim in India. Navidea partner Sayre Therapeutics will lead marketing efforts for the agent through an exclusive license and distribution agreement, the company said.